Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 7/2018

01-07-2018 | Original Article

The POU5F1 gene expression in colorectal cancer: a novel prognostic marker

Authors: Norikatsu Miyoshi, Shiki Fujino, Masayuki Ohue, Masayoshi Yasui, Yusuke Takahashi, Keijiro Sugimura, Akira Tomokuni, Hirofumi Akita, Shogo Kobayashi, Hidenori Takahashi, Takeshi Omori, Hiroshi Miyata, Masahiko Yano

Published in: Surgery Today | Issue 7/2018

Login to get access

Abstract

Purpose

The POU5F1 gene, which encodes the POU domain, class 5, transcription factor 1 (also known as Oct-4), is expressed in embryonic stem cells where it regulates pluripotency and proliferation. Few studies have examined the expression and significance of POU5F1 in cancer tissues. The aim of this study was to clarify its significance in colorectal cancer (CRC).

Methods

The study included 95 patients who underwent surgery for CRC from 2009 to 2011. The correlations between the POU5F1 gene expression and the clinical parameters were assessed in these patients. The serum TP53 expression levels were also examined by an enzyme-linked immunosorbent assay.

Results

Patients with a high POU5F1 expression were significantly more likely to have a poor prognosis than those with a low expression. In contrast, patients with a low POU5F1 expression had a better disease-free survival after curative surgical resection than those with a high expression (P = 0.007). Multivariate analyses showed that the POU5F1 expression (P = 0.003) and lymph node metastasis (P < 0.001) were significantly correlated with the disease-free survival. The prognosis was significantly related to the serum TP53 levels, according to the POU5F1 expression.

Conclusion

The POU5F1 expression was suggested to be a prognostic factor in patients with CRC.
Appendix
Available only for authorised users
Literature
1.
2.
Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007;176:61–80.CrossRefPubMed
3.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for the treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207–39.CrossRefPubMedPubMedCentral
4.
Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: The past, the present and the future. Ann Gastroenterol Surg. 2017;1:5–10.CrossRefPubMedPubMedCentral
5.
Scholer HR, Dressler GR, Balling R, Rohdewohld H, Gruss P. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 1990;9:2185–95.PubMedPubMedCentralCrossRef
6.
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38:431–40.CrossRefPubMed
7.
Cai S, Geng S, Jin F, Liu J, Qu C, Chen B. POU5F1/Oct-4 expression in breast cancer tissue is significantly associated with non-sentinel lymph node metastasis. BMC Cancer. 2016;16:175.CrossRefPubMedPubMedCentral
8.
Sobin LH, Gospodarowicz MK. TNM Classification of Malignant Tumors, seventh edition (2009) Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Wiley, Hoboken, 100–9.
9.
Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24:372–6.CrossRefPubMed
10.
Miyoshi N, Stel JM, Shioda K, Qu N, Odahima J, Mitsunaga S, et al. Erasure of DNA methylation, genomic imprints, and epimutations in a primordial germ-cell model derived from mouse pluripotent stem cells. Proc Natl Acad Sci USA. 2016;113:9545–50.CrossRefPubMedPubMedCentral
11.
Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA. 2010;107:40–5.CrossRefPubMed
12.
Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.CrossRefPubMed
13.
Ferreyra Solari NE, Belforte FS, Canedo L, Videla-Richardson GA, Espinosa JM, Rossi M, et al. The NSL chromatin-modifying complex subunit KANSL2 regulates cancer stem-like properties in glioblastoma that contribute to tumorigenesis. Cancer Res. 2016;76:5383–894.CrossRefPubMedPubMedCentral
14.
Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.CrossRefPubMed
15.
16.
Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.CrossRefPubMed
17.
Bathe OF, Dowden S, Sutherland F, Dixon E, Butts C, Bigam D, et al. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 2004;4:32.CrossRefPubMedPubMedCentral
18.
Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619–25.CrossRefPubMedPubMedCentral
19.
Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009;460:1140–4.CrossRefPubMedPubMedCentral
20.
Zhen HY, Zhou J, Wu HN, Yao C, Zhang T, Wu T, et al. Lidamycin regulates p53 expression by repressing Oct4 transcription. Biochem Biophys Res Commun. 2014;447:224–30.CrossRefPubMed
Metadata
Title
The POU5F1 gene expression in colorectal cancer: a novel prognostic marker
Authors
Norikatsu Miyoshi
Shiki Fujino
Masayuki Ohue
Masayoshi Yasui
Yusuke Takahashi
Keijiro Sugimura
Akira Tomokuni
Hirofumi Akita
Shogo Kobayashi
Hidenori Takahashi
Takeshi Omori
Hiroshi Miyata
Masahiko Yano
Publication date
01-07-2018
Publisher
Springer Singapore
Published in
Surgery Today / Issue 7/2018
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-018-1644-9

Other articles of this Issue 7/2018

Surgery Today 7/2018 Go to the issue

Original Article

Bile duct angulation and tumor vascularity are useful radiographic features for differentiating pancreatic head cancer and intrapancreatic bile duct cancer

Original Article

Postpneumonectomy bronchopleural fistula in non-small cell lung cancer patients: incidence, survival, mortality, and treatment analysis

Original Article

Application of a commercial single-port device for robotic single-incision distal pancreatectomy: initial experience

Review Article

Systematic review of the feasibility and future of laparoscopic liver resection for difficult lesions

Original Article

Additional lymph node dissection for primary colorectal cancer invading another colon region

Original Article

Complication analysis of complete versus partial coverage of tissue expanders using serratus anterior musculofascial flaps in immediate breast reconstruction